This session covers intricate complications involving the left main coronary artery (LMCA), highlighting cases of catheter-induced dissections, challenges in chronic total occlusion (CTO) PCI, and rare scenarios such as stent entrapment and complex re-interventions. Emphasis is placed on the critical utility of intravascular ultrasound (IVUS) and...

This session reviews emerging clinical applications for drug-coated balloons (DCB) beyond traditional indications. It covers outcomes in venous stenosis, aorto-ostial lesions, and coronary bifurcation disease, comparing DCB strategies with drug-eluting stents and highlighting recent clinical trial findings.

This session highlights the pivotal role of imaging in resolving dilemmas during primary percutaneous coronary intervention (PCI). It presents complex cases illustrating challenges such as coronary compression, thrombus burden in large vessels, and culprit lesion identification, including the use of high-definition intravascular ultrasound (HD-IVUS) to reclassify...

This session examines innovations in TAVI care pathways aimed at improving patient outcomes and healthcare efficiency. Topics include large-scale transatlantic data on day-case TAVI, standardized ECG conduction algorithms reducing hospital stay, nurse-led structured pathways, feasibility of very early discharge, and urgent outpatient TAVI for severe aortic...

The ISCHEMIA trial found no significant difference between an invasive vs. a conservative strategy in patients with chronic coronary syndromes and moderate to severe ischemia at a mean of 3.2 years. However, the cumulative difference in the estimates of cardiac death between the invasive and conservative...

Paris, France, 20-23 May 2025. The EuroPCR Course Directors have selected 3 major late-breaking trials that will be presented for the first time during the 2025 edition of EuroPCR. These trials were selected because of their design, results, and potential to impact practice, among which is the...

Ali Nazmi Calik provides his take on the results of the OPTIMAL trial presented by Luca Testa at ACC.26 in New Orleans.

In this article, Bruno Scheller explores advances in local drug delivery, from drug-coated balloons to novel antiproliferative agents. These innovations aim to reduce restenosis, minimize permanent implants, and pave the way for patient-specific coronary artery disease treatments.